WAM
CHRS icon

Wakefield Asset Management’s Coherus Oncology CHRS Stock Holding History

Wakefield Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-28,436
Closed -$522K – 164
2020
Q3 		$522K Buy
28,436
+220
+0.8% +$4.09K 0.25% 112
2020
Q2 		$504K Sell
28,216
-5,954
-17% -$101K 0.24% 118
2020
Q1 		$554K Buy
34,170
+4,460
+15% +$82.4K 0.3% 79
2019
Q4 		$535K Buy
+29,710
New +$548K 0.22% 121

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wakefield Asset Management's CHRS Position: Q4 2020 in Review

Wakefield Asset Management sold out of Coherus Oncology (CHRS) in Q4 2020, closing a stake of 28,436 shares — an estimated $522K sold.

Wakefield Asset Management first reported a position in CHRS in Q4 2019 and held it in 4 quarters. The position peaked at $554K in Q1 2020. 196 funds tracked by Wall St. Rank hold CHRS as of Q4 2020.

  • Wakefield Asset Management reported no remaining Coherus Oncology position as of Q4 2020 after selling out during the quarter.
  • Wakefield Asset Management sold 28,436 Coherus Oncology shares in Q4 2020, an estimated $522K.
  • Wakefield Asset Management first reported a position in Coherus Oncology in Q4 2019 and held it in 4 quarters.
  • Wakefield Asset Management's Coherus Oncology position peaked at $554K in Q1 2020.
  • 196 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2020.

Based on Wakefield Asset Management's 13F filing for Q4 2020, filed 8 Feb 2021.